|
|
Volumn 61, Issue 5, 2013, Pages 594-595
|
|
Bioequivalence in the real world is a complex challenge: The case of clopidogrel
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOSINE DIPHOSPHATE;
ARACHIDONIC ACID;
CITRATE SODIUM;
CLOPIDOGREL;
ACUTE CORONARY SYNDROME;
ADULT;
AGE;
ANTICOAGULATION;
BIOEQUIVALENCE;
BLOOD ANALYSIS;
CARDIOVASCULAR MORTALITY;
CARDIOVASCULAR RISK;
CORONARY STENT;
DIABETES MELLITUS;
DISEASE ASSOCIATION;
DISEASE COURSE;
DRUG STRUCTURE;
DYSLIPIDEMIA;
FEMALE;
FOLLOW UP;
HEART DISEASE;
HEART MUSCLE REPERFUSION;
HIGH RISK PATIENT;
HUMAN;
HYPERTENSION;
INCIDENCE;
LETTER;
LIGHT TRANSMISSION AGGREGOMETRY;
MAJOR CLINICAL STUDY;
MALE;
NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;
PATIENT IDENTIFICATION;
PERCUTANEOUS CORONARY INTERVENTION;
PLATELET REACTIVITY;
PREVALENCE;
PRIORITY JOURNAL;
RECURRENT DISEASE;
SEX DIFFERENCE;
SMOKING;
ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;
THROMBOCYTE AGGREGATION INHIBITION;
AGED;
AGED, 80 AND OVER;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
MYOCARDIAL INFARCTION;
PLATELET ACTIVATION;
PLATELET AGGREGATION INHIBITORS;
THERAPEUTIC EQUIVALENCY;
TICLOPIDINE;
|
|
EID: 84873078318
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2012.10.020 Document Type: Letter |
|
Times cited : (18)
|
|
References (6)
|
